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Abstract: Macropinocytosis is a unique pathway of endocytosis characterised by the nonspecific
internalisation of large amounts of extracellular fluid, solutes and membrane in large endocytic
vesicles known as macropinosomes. Macropinocytosis is important in a range of physiological
processes, including antigen presentation, nutrient sensing, recycling of plasma proteins, migration
and signalling. It has become apparent in recent years from the study of specialised cells that there are
multiple pathways of macropinocytosis utilised by different cell types, and some of these pathways
are triggered by different stimuli. Understanding the physiological function of macropinocytosis
requires knowledge of the regulation and fate of the macropinocytosis pathways in a range of cell
types. Here, we compare the mechanisms of macropinocytosis in different primary and immortalised
cells, identify the gaps in knowledge in the field and discuss the potential approaches to analyse the
function of macropinocytosis in vivo.
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1. Introduction
Endocytosis is a process carried out by eukaryotic cells that facilitates the internalisation of
extracellular molecules and plasma membrane components. Over the past 15–20 years, it has become
clear that there are many distinct pathways of endocytosis that promote the internalisation of a range
of extracellular molecules, either via specific or nonspecific mechanisms [1]. Macropinocytosis is
one of the nonspecific endocytic pathways that has gained considerable recent attention, as this
pathway has the unique property of rapidly internalising very large amounts of plasma membrane
and extracellular fluid and functions in a range of physiological processes including nutrient uptake
and nutrient sensing, signalling, antigen presentation and cell migration [2–5]. Macropinocytosis can
also be exploited by pathogens such as bacteria, viruses, protozoa and prions to invade host cells [2,6].
Although macropinocytosis has only recently attracted attention in mainstream biology, Warren Lewis
first described the morphological characteristics of this pathway in the 1930s, when he showed that
macrophages and cancer cells ruffle and consequently internalise extracellular fluid [7,8].
Unlike other endocytic pathways such as receptor-mediated endocytosis and phagocytosis,
macropinocytosis is not initiated by binding of cargo molecules to cognate cell surface receptors
or contact of large particles with the cell surface, and is therefore not saturable [5]. Instead,
macropinocytosis is initiated by the polymerisation of actin at the plasma membrane to generate
extensions called membrane ruffles [2]. These ruffles may originate from the leading edge of cells
(peripheral membrane ruffles) and fold backwards or from the dorsal surface of cells (dorsal membrane
ruffles) to give rise to circular cups [9]. Ruffles can trap solutes into large (0.2–5 µm in diameter),
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irregular-shaped vesicles called macropinosomes [2]. Macropinosomes can subsequently undergo
homotypic fusion and fission and also traffic to other organelles in the endolysosomal system [10].
Much of the early work on macropinocytosis was focused on the immune cells, dendritic cells
and macrophages. However, the range of cell types capable of macropinocytosis is now recognised to
include not only dendritic cells and macrophages, but also B and T cells, epithelial and endothelial cells,
fibroblasts, neurons, microglia and cancer cells. While some of these cell types only show appreciable
macropinocytosis in response to growth factor stimulation or exposure to pathogens, for example
epithelial cells [11], other cell types can macropinocytose constitutively, such as immature dendritic
cells [12–14], macrophages [15] and cancer cells [16]. As macropinocytosis is the most efficient way
for cells to internalise large amounts of extracellular fluid and plasma membrane, this pathway has a
significant impact on the physiology of these cells.
It is becoming increasingly apparent that macropinocytosis is not identical in different cell types;
rather, macropinocytosis is regulated by different stimuli and unique molecular machinery in specific
cell types. For example, sorting nexin 5 (SNX5) has been identified as a critical regulator of dorsal
ruffling and macropinocytosis in macrophages [9,17] but does not affect macropinocytosis in splenic
dendritic cells [9]. Moreover, the fate of macropinosome maturation also varies between different cells;
in some cases, macropinosomes are transported along the endosomal–lysosomal pathway [18]; and
in other cases, macropinosomes are recycled back to the PM [15]. Furthermore, the same molecular
machinery can be utilised for different aspects of macropinocytosis in different cell types. For example,
phosphoinositide 3-kinase (PI3K) regulates macropinocytosis by promoting macropinosome closure in
macrophages [19] but regulates membrane ruffling in endothelial cells [20]. In addition, the Na+/H+
exchanger inhibitor amiloride robustly inhibits macropinocytosis in macrophages [21], whereas it does
not inhibit macropinocytosis in dendritic cells [22].
The finding that there are differences in the macropinocytosis pathways in different cell types
highlights the importance of interrogating macropinocytosis in a range of specialised cell types,
particularly in physiologically relevant primary cells. There have been a number of reviews
on macropinocytosis which have provided an excellent integrated critique of this pathway [2–5].
This review aims to focus on the current status of our understanding of macropinocytosis in primary
cells, to compare the molecular mechanisms of this pathway between the different cell types, and to
highlight the gaps in knowledge.
Analysing Macropinocytosis
Despite its importance to physiology, the molecular mechanisms underlying macropinocytosis
remain only partly understood. This is largely due to the difficulty in studying macropinocytosis. Unlike
clathrin-coated vesicles derived from clathrin-mediated endocytosis, macropinosomes have no apparent
coat structure [2] and currently no unique molecules present on macropinosome membranes have
been identified. Instead, macropinosomes are typically labelled with fluorescently-tagged fluid-phase
markers that are known to be predominantly internalised by macropinocytosis, such as dextran, Lucifer
yellow, albumin, ovalbumin and horseradish peroxidase (HRP) [10,12,23,24]. Labelling with fluid-phase
markers has the limitation in that uptake by other endocytic processes can also contribute. For example,
dextran, ovalbumin and HRP are also internalised by mannose receptor-mediated endocytosis [12,25].
Dextran is one of the most commonly used macropinosome markers, and a range of dextran sizes have
been used to identify macropinosomes, typically between 3 and 70 kDa. Further, 70 kDa dextran has
been shown to be more selective for labelling of macropinosomes compared with 10 kDa dextran [26]
and, perhaps not surprisingly, (micro)pinocytosis has been shown to make a significant contribution to
the uptake of smaller 3 kDa dextran [19]. These limitations in the specificity of fluid-phase markers for
macropinocytosis highlight the need to identify macropinosome-specific molecules.
An additional difficulty in studying macropinocytosis is the lack of drugs that specifically
inhibit this process [27]. Drugs that have been commonly used for this purpose target actin
polymerisation, which is required for macropinocytosis. These include cytochalasins, which bind to
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actin filaments and prevent their polymerisation [28,29] and latrunculins, which bind to and sequester
monomeric actin [29,30]. PI3K inhibitors such as wortmannin and LY294002 are often used to inhibit
macropinocytosis through the inhibition of actin polymerisation [28]. However, these drugs are
not specific for macropinocytosis, as other endocytic pathways such as phagocytosis also require
actin polymerisation [27]. To date, the most selective inhibitors of macropinocytosis are members
of the amiloride family, including amiloride and its analogues 5-(N-ethyl-N-isopropyl)amiloride
(EIP-amiloride) and 5-(N,N-dimethyl)amiloride (dimethyl amiloride), which inhibit the activity
of Na+/H+ exchangers [11,30]. Inhibition of Na+/H+ exchangers leads to acidification of the
submembranous cytosol with a subsequent failure in recruitment of the small GTPases Rac1 and Cdc42
to the plasma membrane, and the inhibition of actin polymerisation [30]. However, as amiloride and
its analogues have effects on other cellular processes, they cannot be considered specific inhibitors of
macropinocytosis [31].
2. Non-Mammalian Systems
Macropinocytosis has been studied in a number of non-mammalian organisms. These include the
amoebae Dictyostelium, where macropinocytosis facilitates the acquisition of nutrients for their
growth in liquid culture [32]. Studies in Dictysostelium have revealed the requirement for the
phosphoinositide PI(3,4,5)P3 and the small GTPases Ras and Rac, which are recruited to patches of
the plasma membrane [33]. Furthermore, using lattice light-sheet microscopy (LLSM), Veltman and
colleagues demonstrated that the actin-driven cup projections in Dictyostelium formed around these
patches of PI(3,4,5)P3, Ras and Rac [34]. Caenorhabditis elegans has also been a useful model to study
macropinocytosis in vivo, as scavenger cells known as coelomocytes can non-specifically internalise
fluid-phase markers such as 40 kDa dextran and albumin injected into its body cavity [35]. The
ability to visualise the internalisation of injected dextran into the body cavity, as well as the ability
to readily genetically manipulate these organisms, has allowed the interrogation of various aspects
of macropinocytosis such as the trafficking of different-sized dextrans [26] and genes involved
in phosphoinositide metabolism [36]. When injected into the embryo, Drosophila melanogaster
hemocytes are capable of internalising 70 kDa dextran into large vesicles (typically 1–4 µm in
diameter), suggesting that these cells are also capable of macropinocytosis [37]. Given these features,
Drosophila has considerable potential as a model system to define the mechanisms of macropinocytosis
in whole organisms.
3. Mammalian Cells
3.1. Immune Cells
3.1.1. Dendritic Cells
Dendritic cells (DCs) initiate immune responses through the presentation of peptide–MHC
complexes at their surface, leading to recognition of the peptide antigen–MHC complex and activation
of T cells [38]. The ability of DCs to efficiently present peptide–MHC complexes is in part attributed to
their ability to efficiently capture antigens by macropinocytosis [12,14]. DCs, in addition to macrophages,
are the most well-studied cell types with respect to macropinocytosis. Distinct subclasses of DCs are
identified under steady-state conditions, namely conventional DCs (cDCs) and plasmacytoid DCs
(pDCs) [39]. cDCs can be further subdivided into cDC1 and cDC2 populations, which show differences
in the pathways of antigen presentation resulting in different downstream T cell responses [39]. Several
DC populations have been used to study macropinocytosis. These include primary DCs isolated from
mouse spleen [39] and DCs derived from the differentiation of DC precursors from mouse bone marrow
with GM-CSF (bone marrow-derived dendritic cells (BMDCs)) [40]. Human monocyte-derived DCs
have also been used as a DC model [41].
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Role of Macropinocytosis in Antigen Presentation by DCs
Macropinocytosis is utilised by DCs to facilitate uptake of extracellular antigens, a process called
antigen capture, for subsequent intracellular processing of antigens into antigenic peptides, which
is required for generation of peptide–MHC complexes. Type II collagen (CII) is a long (~300 nm)
autoantigen molecule implicated in collagen-induced arthritis in mice and rheumatoid arthritis in
humans and is internalised by macropinocytosis in mouse BMDCs [42]. Importantly, amiloride
blocks presentation of CII antigen to T cells both in vitro and in vivo, highlighting the therapeutic
potential of blocking macropinocytosis in the context of autoimmune diseases [42]. Uptake of RNA by
macropinocytosis has also been demonstrated in human monocyte-derived DCs, a finding relevant to
the development of antigen-encoding RNA vaccines [43]. Evidence for the role of macropinocytosis in
DC antigen presentation is also revealed through the analysis of the trafficking of fluid-phase markers.
In human monocyte-derived DCs, internalised 40 kDa dextran is initially localised to macropinosomes
in the periphery of the cell and subsequently trafficked to MHC II-expressing lysosomes, demonstrating
that macropinosome content is delivered to MHC II-loading compartments in DCs [12] (Figure 1A).
The process of macropinocytosis, and associated plasma membrane turnover, is also proposed to
facilitate uniform migration of DCs in their environment, thus allowing them to function as efficient
antigen sampling cells [44].
Constitutive Macropinocytosis in DCs and the Effect of Activating Stimuli
In contrast to many other cell types, macropinocytosis in DCs is a constitutive process,
which enables them to function as sentinel cells that constitutively capture antigens [12–14]. Constitutive
macropinocytosis in the absence of defined stimulatory factors has been demonstrated for both mouse
BMDCs [14] and mouse splenic DCs [13]. Constitutive macropinocytosis in human monocyte-derived
DCs depends on extracellular calcium and the calcium-sensing receptor (CaSR), a G protein-coupled
receptor [45]. Furthermore, plasma membrane-localised phosphatidic acid is required for constitutive
membrane ruffling and macropinocytosis in mouse BMDCs [46]. The role of extracellular calcium,
CaSR and phosphatidic acid in constitutive macropinocytosis is described in more detail below
for macrophages.
The activation status of DCs is considered to regulate their ability to macropinocytose. In most
tissues, DCs are present in an “immature” state, specialising in antigen capture by endocytic processes
such as macropinocytosis [12,14]. Following antigen capture, DCs become activated or “mature”,
migrating to T cell-dependent areas of secondary lymphoid organs and losing their ability to efficiently
acquire antigens [12,38]. For example, immature BMDCs can internalise ovalbumin whereas mature
BMDCs show no uptake [47]. It has been suggested that antigen-presenting mature DCs may
downregulate macropinocytosis as any additional uptake of antigens is not necessary and, furthermore,
macropinocytosis may interfere with antigen presentation as a consequence of promoting internalisation
of peptide–MHC complexes from the cell surface [48].
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compartments. (B). Macrophages can internalise substantial amounts of extracellular fluid and solutes 
in response to growth factor stimulation, which are trafficked to lysosomes or alternatively recycled 
to the cell surface via tubular carriers. (C). Epithelial cells show low levels of macropinocytosis at rest, 
but pathogens such as bacteria can induce macropinocytosis to facilitate their internalisation. (D). 
Cancer cells expressing oncogenic Ras constitutively macropinocytose, which facilitates the uptake of 
extracellular nutrients which activate mTOR signalling and drive growth and proliferation. 
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Molecular Machinery Involved in Macropinocytosis by DCs
The small GTPases Rac1 and Cdc42, which are involved in actin polymerisation [49], are key
regulators of constitutive macropinocytosis in DCs. Microinjection of dominant-negative Rac1 or
dominant-negative Cdc42 into immature BMDCs inhibits macropinocytosis and microinjection of
constitutively active Rac1, or constitutively active Cdc42, increases macropinocytosis in mature
BMDCs [47]. Similar findings have been reported for macropinocytosis in splenic DCs; microinjection
of dominant-negative forms of Rac1 or Cdc42 leads to a decrease in macropinocytosis [13]. As neither
dominant-negative Rac1 nor dominant-negative Cdc42 inhibit membrane ruffling in splenic DCs, it is
likely that Rac1 and Cdc42 regulate macropinocytosis downstream of membrane ruffling [13].
The effect of inhibiting other cellular machinery on macropinocytosis in DCs has also been
evaluated. Inhibition of PI3K with wortmannin in splenic DCs inhibits macropinocytosis without
inhibiting membrane ruffling, suggesting that similar to Rac1 and Cdc42, the regulation of
macropinocytosis by PI3K in DCs occurs downstream of membrane ruffling [13]. Rapamycin
inhibits macropinocytosis in BMDCs and splenic DCs, suggesting that mTOR signalling regulates
macropinocytosis in DCs [50]. Inhibition of aquaporins also decreases macropinocytosis in human
monocyte-derived DCs [51]. The glucocorticoid-induced leucine zipper protein (GILZ) is also a
regulator of macropinocytosis in DCs [52]. GILZ negatively regulates macropinocytosis, although this
varies depending on the DC subset; GILZ inhibits macropinocytosis in splenic cDC1 and BMDCs but
not splenic cDC2 and splenic pDCs [52].
3.1.2. Macrophages
Macrophages are key innate immune cells that have various functions including phagocytosis,
antigen presentation, tissue repair and cytokine production [53]. Macropinocytosis is important for
a number of these functions. Our understanding of the different pathways of macropinocytosis,
such as constitutive versus growth factor-induced macropinocytosis, and dorsal versus peripheral
ruffling pathways of macropinocytosis, largely result from the studies using macrophages.
Macrophages from a variety sources have been used to study macropinocytosis, in particular
primary mouse bone marrow-derived macrophages (BMDMs) [9,17], primary mouse peritoneal
macrophages [17], the macrophage cell line RAW 264.7 [54,55] and human monocyte-derived
macrophages (hMDMs) [45,56].
Constitutive and Activated Macropinocytosis in Macrophages
Macropinocytosis occurs constitutively in macrophages [15] and is enhanced in response to
growth factors such as macrophage colony-stimulating factor (CSF-1) [45] and to pathogen-derived
molecules such as lipopolysaccharide (LPS) [54]. Constitutive macropinocytosis generates smaller
macropinosomes than those arising after cell stimulation [45], whereas CSF-1 [45] and LPS [54]
stimulation results in the formation of larger macropinosomes.
The molecular basis of constitutive macropinocytosis in macrophages has recently been
elucidated [45]. Constitutive macropinocytosis, but not growth factor- or pathogen-induced
macropinocytosis, is dependent on extracellular calcium and CaSR, which is expressed in myeloid
cells such as monocytes, macrophages and DCs [45]. Removal of extracellular calcium, inhibition
of CaSR with the selective antagonist NPS2143 and inhibition of Gα proteins with BIM46187 all
inhibit constitutive macropinocytosis in primary hMDMs [45]. Based on these findings, a model
for constitutive macropinocytosis has been proposed [45]. Extracellular calcium activates CaSR,
allowing Gα to activate PI3K which in turn generates PI(3,4,5)P3 at the plasma membrane. PI(3,4,5)P3
then recruits phospholipase C (PLC), leading to hydrolysis of PI(4,5)P2 to diacylglycerol (DAG) and
inositol triphosphate (IP3). DAG is phosphorylated by diacylglycerol kinase (DGK) to generate
phosphatidic acid, which drives actin polymerisation, constitutive membrane ruffling and constitutive
macropinocytosis. Phosphatidic acid drives actin polymerisation by a number of mechanisms including
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the recruitment of TIAM1, a Rac guanine nucleotide exchange factor (GEF), to the plasma membrane
that activates Rac, which is essential for actin polymerisation [46]. While phosphatidic acid is a key
driver of constitutive macropinocytosis, phosphatidic acid is also implicated in phagocytosis [57],
highlighting the common machinery utilised by both pathways.
Membrane Ruffling, Macropinocytosis and Signalling in Macrophages
The peripheral and dorsal ruffling pathways that lead to macropinocytosis have recently been
characterised in CSF-1-stimulated BMDMs. Figure 2 shows an example of dorsal ruffles following
CSF-1-stimulation of BMDMs by scanning electron microscopy. SNX5, a member of the sorting
nexin family of proteins which bind to phosphoinositides via their phox (PX) domains, is a key
regulator of macrophage macropinocytosis [17]. SNX5-deficient BMDMs stimulated with CSF-1 show
a 60–70% reduction in macropinocytic activity compared to their wild-type counterparts [9]. CSF-1
is able to increase peripheral, but not dorsal ruffling in SNX5-deficient BMDMs, demonstrating that
SNX5 is essential for dorsal ruffling but not peripheral ruffling in macrophages [9]. In addition,
knockdown of SNX5 in primary BMDMs resulted in smaller macropinosomes (1–2 µm in diameter)
than wild-type BMDMs (up to 4 µm in diameter), suggesting that dorsal ruffling generates larger
macropinosomes [17]. Together, these data suggest that dorsal ruffling is the major pathway of
macropinocytosis in CSF-1-stimulated BMDMs [9]. A model for the role of SNX5 in dorsal ruffling has
been proposed [9]: CSF–1 receptor activation leads to increased PI(3,4)P2 and SNX5 recruitment to the
plasma membrane where it can promote actin polymerisation and dorsal ruffling. Interestingly and
in contrast to primary macrophages, SNX5 deficiency does not affect macropinocytosis in immature
splenic DCs, implying that different mechanisms of macropinocytosis are utilised by these two immune
cells [9].
The mechanism of dorsal ruffle formation in macrophages has been visualised in LPS-activated
RAW 264.7 cells using LLSM [54]. The analysis by high-resolution LLSM revealed a novel mechanism
to form macropinosomes and also accounted for the large macropinosomes derived from dorsal ruffles.
Two filamentous actin (F-actin)-containing filopodial-like extensions (“tent poles”) are erected and
subsequently elevate a sheet of F-actin, thereby forming a nascent membrane ruffle. The tent poles
circularise to form a circular membrane ruffle. The tent poles cross over each other, constricting the ruffle
and causing it to sink into the cell, thus leading to internalisation of a large nascent macropinosome.
Rab13 is essential for the generation of the LPS-stimulated tent pole dorsal ruffles and macropinosome
formation [54]. Thus, it is clear that there are two distinct macropinocytosis pathways in macrophages
which arise from distinct membrane ruffling events and which utilise distinct mechanisms to generate
the macropinosomes from these ruffles.
Other machinery has been implicated in macrophage macropinocytosis. Inhibition of PI3K with
wortmannin leads to a reduction in macropinocytosis in BMDMs [19]. Peripheral and dorsal ruffles still
form in wortmannin-treated BMDMs but do not close to form macropinosomes; rather, they recede back
into the cytoplasm, showing that PI3K is required for macropinosome closure [19]. Phosphoinositides
are also key regulators of macropinocytosis, as described in a number of reviews [49,58]. The sequential
accumulation and breakdown of phosphoinositide species, as well as the role of small GTPases
in macropinocytosis, have been mapped in CSF-1-stimulated BMDMs and the maturation process
defined [59].
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Effect of Macrophage Functional State on Macropinocytosis
Following activation, macrophages can differentiate into different functional states defined
by their profile of secreted cytokines. For instance, pro-inflammatory macrophages (classically
activated, M1) kill pathogens and present antigens to the adaptive immune system, whereas
anti-inflammatory macrophages (alternatively activated, M2) subsequently clear inflammation and
repair tissue damage [48]. While anti-inflammatory hMDMs show substantial macropinocytosis,
pro-inflammatory hMDMs show very little [48]. The low level of macropinocytosis in pro-inflammatory
macrophages is attributed to reduced CaSR signalling leading to reduced PI3K activity compared
with anti-inflammatory macrophages [48]. As a result, there is decreased production of plasma
membrane PI(3,4,5)P3 and consequently decreased recruitment of GEFs that activate GTPases required
for macropinocytosis (e.g., TIAM1 for Rac1) [48]. Similar to activated DCs, it has been suggested that
antigen-presenting pro-inflammatory macrophages may downregulate macropinocytosis to optimise
antigen presentation as uptake of antigens is no longer necessary [48].
Macropinosome Maturation in Macrophages
The maturation pathway of macropinosomes in CSF-1-stimulated BMDMs has been described [18].
Newly formed macropinosomes are positive for the transferrin receptor (TfR), a marker for early
endosomes. The macropinosomes then mature, losing TfR but acquiring Rab7 and lgp-A, markers of
late endosomes and lysosomes, respectively. The maturing macropinosomes lose Rab7 but continue to
acquire lgp-A, before fusing with tubular lysosomes. During this process, the maturing macropinosomes
shrink and migrate centripetally towards the nucleus. Macropinosome shrinkage in CSF-1-stimulated
BMDMs can be attributed to the removal of membrane into tubular structures that mediate recycling
of macropinocytosed ligands (e.g., albumin) back to the cell surface [21] (Figure 1B). In addition to its
role in dorsal ruffling, SNX5 also appears to play a role in the tubulation of macropinosomes [64].
Functions of Macropinocytosis in Macrophages
Macropinocytosis is critical to a variety of macrophage physiological processes. As for DCs,
macropinocytosis serves as a key pathway of antigen uptake. The more potent amiloride analogue
dimethyl amiloride blocks both constitutive macropinocytosis and phorbol myristate acetate
(PMA)-stimulated ovalbumin antigen presentation on MHC class I molecules [15]. Constitutive
macropinocytosis also contributes to the sentinel function of macrophages by facilitating uptake and
delivery of pattern-recognition receptor ligands (e.g., NOD2 ligands) to their intracellular receptors [45].
Macropinocytosis is also the major pathway for internalisation of plasma immunoglobulin G (IgG) and
albumin by BMDMs; these internalised plasma proteins are subsequently recycled from newly formed
macropinosomes back to the cell surface in a pathway dependent on the neonatal Fc receptor (FcRn) [21].
Macrophage macropinocytosis is also implicated in disease and infection. Macropinocytosis contributes
to low-density lipoprotein (LDL) uptake and cholesterol accumulation in hMDMs and is therefore
relevant to the development of atherosclerosis [56]. In addition, macrophages are a target of human
immunodeficiency virus 1 (HIV-1) infection and HIV-1 is internalised into large vesicles resembling
macropinosomes (200 to >500 nm in diameter) in hMDMs [65]. Dimethyl amiloride treatment was
able to inhibit HIV-1 replication, suggesting a key role for macropinocytosis in the propagation of the
virus [65].
3.1.3. B Cells and T Cells
B cells not only differentiate into antibody-producing plasma cells, but can also act as
antigen-presenting cells by internalising antigens through their B cell receptors (BCRs), and by
processing the internalised antigens and presenting the processed peptides on MHC II molecules to T
cells [66]. While B cells have not previously been considered candidates for active macropinocytosis,
a recent study has indicated that B cells are capable of macropinocytosis in the context of pathogen
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infection. Raji cells, a human B lymphoblast cell line, exhibits very little membrane ruffling
and macropinocytosis at rest [67]. However, upon PMA treatment or infection of Raji cells with
Salmonella typhimurium, Mycobacterium tuberculosis or Mycobacterium smegmatis, membrane ruffling
and macropinocytosis is upregulated [67]. Mycobacterium tuberculosis and Mycobacterium smegmatis
supernatants are also able to induce membrane ruffling and macropinocytosis, suggesting that secreted
soluble bacterial factors may be responsible [67].
CD8+ T cells directly kill pathogen-infected cells and CD4+ T cells secrete cytokines that help
the activity of other cells (e.g., B cells and macrophages) to generate an effector immune response.
As for B cells, T cells have not traditionally been considered candidates for active macropinocytosis.
However, recently, both primary mouse and human CD4+ and CD8+ T cells have been shown to exhibit
significant basal levels of macropinocytosis and, moreover, the basal levels are increased upon cell
activation [68]. Treatment with EIP-amiloride not only blocks macropinocytosis by non-activated and
activated T cells, but also reduces mTORC1 activation and T cell growth [68]. These findings suggest a
model whereby macropinocytosis mediates uptake of amino acids required for activation of mTORC1
and as a result, growth of T cells [68]. Macropinocytosis has also been implicated in the uptake of
single-stranded antisense oligonucleotides flanked by locked nucleic acids (LNAs), called GapmeR,
to successfully knockdown genes in primary human T cells [69]. In addition, the internalisation of
lentiviral vectors pseudotyped with measles virus envelope glycoproteins into unstimulated human
peripheral blood T cells appears to be via macropinocytosis based on inhibition of entry with known
inhibitors such as amiloride [70]. These recent findings highlight key roles for macropinocytosis in T
cell responses and also the infection of T cells.
3.2. Endothelial and Epithelial Cells
Various endothelial and epithelial cells have been used to study growth factor-induced
macropinocytosis. Both of these cell types are polarised with apical and basolateral plasma membrane
domains separated by tight junctions. Endothelial cells line blood and lymphatic vessels, with the apical
surface facing the lumen of the vessels, whereas epithelial cells line surfaces of the body, such as lung,
small intestine and urinary tract, with the apical surface facing the external environment. Although
the majority of studies exploring macropinocytosis in these cells have utilised immortalised cell lines,
they have nonetheless provided valuable insights into molecular mechanisms of macropinocytosis.
3.2.1. Endothelial Cells
Macropinocytosis is relevant to various aspects of endothelial cell biology. These cells exhibit low
levels of constitutive macropinocytosis, but can upregulate macropinocytosis in response to growth
factors. For example, cultured porcine aortic endothelial (PAE) cells show low levels of basal membrane
ruffling but upregulate PI(3,4,5)P3 levels and membrane ruffling in response to platelet-derived growth
factor (PDGF) [20]. PDGF-stimulated PI(3,4,5)P3 production and membrane ruffling in these cells is
dependent on PI3K [20].
Endothelial cells can also be the natural infection targets of viruses, which can exploit a variety of
endocytic pathways for uptake, including macropinocytosis (reviewed in [6]). For example, HIV-1 enters
primary human brain microvascular endothelial cells (BMVECs) via a pathway of macropinocytosis
that appears to require cholesterol and MAPK signalling [71]. The majority of internalised HIV-1
particles are then trafficked to lysosomes for degradation [71]. Entry of Kaposi’s sarcoma-associated
herpesvirus (KSHV) into primary human microvascular dermal endothelial cells (HMVEC-d) and
human umbilical vein endothelial cells (HUVECs) is also via macropinocytosis [72]. KSHV infection
significantly increases membrane ruffling and 70 kDa dextran uptake in both cell types, whose levels
are low in the absence of infection [72]. Invasion of the bacterium Escherichia coli K1 into human brain
microvascular endothelial cells (HBMECs) is also via macropinocytosis [73].
Macropinocytosis is also relevant to key cellular processes in endothelial cells including regulation
of gene expression and metabolism. The gene expression profile of hCMEC/D3 cells, a human brain
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microvascular endothelial cell line that is a model for the blood–brain barrier, is altered by the uptake
of neutrophil-derived microvesicles [74]. Macropinocytosis contributes to the cellular uptake of these
microvesicles based on a reduction in uptake on treatment with either EIP-amiloride, cytochalasin
D or wortmannin, although the clathrin-mediated endocytosis inhibitor monodansylcadaverine also
reduces uptake [74]. HUVECs also upregulate macropinocytosis on glutamine deprivation to facilitate
the uptake of non-essential amino acids and to drive proliferation [75]. One of the limitations in the
study of endothelial cells is the lack of primary cell cultures. The recent advance in generation of
human primary endothelial cells from blood (blood outgrowth endothelial cells) [76] should provide a
valuable source of primary endothelial cells in the future for detailed analysis of the macropinocytosis
pathway in this polarised cell.
3.2.2. Epithelial Cells
Madin–Darby Canine Kidney (MDCK) cells have proven to be a useful cell line to investigate
the effect of cell polarity on macropinocytosis. From these studies, it is clear that the apical and
basolateral surfaces of polarised epithelial cells differ in their levels of macropinocytosis. The apical
surface of polarised MDCK cells shows membrane ruffling and macropinocytosis in response to
N-ethylmaleimide treatment but not the basolateral surface [77]. The resulting macropinosomes from
the apical surface remain in the apical cytoplasm and do not fuse with other endocytic organelles [77].
The viral oncoprotein v-Src also increases the uptake of HRP from the apical but not basolateral
surface in MDCK cells, which is attributed to the induction of apical ruffling and macropinocytosis [78].
The resulting apical macropinosomes, in contrast to N-ethylmaleimide-induced apical macropinosomes,
are thought to fuse with the apical recycling endosome [78].
In addition to MDCK cells, a wide variety of other epithelial cells have been used to interrogate the
mechanisms of macropinocytosis and its physiological relevance. A431 human epidermoid carcinoma
cells are one of the most commonly used epithelial cell lines to study macropinocytosis. Basal levels of
macropinocytosis in these cells is low, but can be increased upon the addition of epidermal growth factor
(EGF) [11]. Macropinosomes induced by EGF stimulation avoid trafficking to transferrin-labelled early
and recycling endosomes and LDL-labelled late endosomes and lysosomes [79] and instead recycle
to the plasma membrane [15]. These EGF-stimulated macropinosomes are capable of tubulating and
fusing with one another [79]. The use of EGF-stimulated A431 cells has also identified the CtBP1/BARS
protein as a regulator of macropinosome closure [80] and elucidated the mechanism by which amiloride
inhibits macropinocytosis [30]. Various stimulators of macropinocytosis have been identified in other
epithelial cells. For example, binding of arginine-rich peptides to cell surface proteoglycans leads to
Rac1 activation and macropinocytosis in the Chinese hamster ovary (CHO) cell line [81] and lipids
bound to albumin such as free fatty acids stimulate macropinocytosis in immortalised podocytes,
epithelial cells which form the filtration barrier of the kidney [82].
Like endothelial cells, epithelial cells are also natural infection targets of numerous pathogens
including bacteria and viruses, which can exploit macropinocytosis to gain entry (Figure 1C).
A549 is a human lung epithelial cell line with low levels of ruffling and macropinocytosis;
infection with Mycobacterium smegmatis or Mycobacterium tuberculosis increases membrane ruffling
and macropinocytosis [83]. Incubation with the Mycobacterium supernatants also increases
macropinocytosis, suggesting that secreted soluble bacterial factors are responsible for the induction of
macropinocytosis [83]. Macropinocytosis is also exploited by other bacteria for internalisation, such as
the entry of invasive Salmonella typhimurium into HEp-2 epithelial cells [84] and the entry of Neisseria
gonorrhoeae into primary human urethral epithelial cells (HUECs) [85]. Various viruses also exploit
macropinocytosis to mediate their entry into epithelial cells. Ebola virus uses dynamin-dependent
macropinocytosis to enter Vero cells, a monkey kidney epithelial cell line [86] and echovirus 1 uptake into
polarised Caco-2 cells, a human colon cancer cell line, depends on macropinocytosis [87]. In addition,
different pathways of macropinocytosis can be utilised by viruses to gain entry into epithelial cells.
Western Reserve (WR) and International Health Department-J (IHD-J) are closely related strains of
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the Vaccinia virus, and both stimulate macropinocytosis to facilitate their internalisation into HeLa
cells, a human cervical cancer epithelial cell line [88]. However, infection with WR Vaccinia virus
is sensitive to PI3K inhibition whereas infection with IHD-J Vaccinia virus is not [88]. Furthermore,
infection with WR Vaccinia virus is highly dependent on Rac1, whereas infection with IHD-J is highly
dependent on Cdc42, highlighting the existence of different pathways of macropinocytosis that can
be exploited by viruses [88]. Spherical influenza virus can enter cells by both macropinocytosis and
by clathrin-mediated endocytosis whereas the larger filamentous influenza virus is likely to enter
epithelial cells mainly by macropinocytosis [89,90]. Thus, macropinocytosis is an entry portal for many
infectious pathogens that invade epithelial layers.
3.3. Fibroblasts
Fibroblasts are found in connective tissue and synthesise and secrete key extracellular matrix
molecules such as collagen. Fibroblast cell lines have been frequently used as a cell model to study
macropinocytosis and to identify the relevant molecular regulators. For example, the importance of
Rac1 to macropinocytosis was demonstrated in these cells. Microinjection of activated Rac1 into Rat2
fibroblasts, which have low levels of constitutive macropinocytosis, drastically increased bulk-phase
pinocytosis which was considered to be due to macropinocytosis [91]. Similarly, microinjection of
activated Rac1 into 3T3 mouse fibroblasts, which exhibit low levels of membrane ruffling, dramatically
increases membrane ruffling [91]. Peripheral and dorsal ruffling pathways have also been studied in
fibroblasts. Unstimulated AG 1523 human foreskin fibroblasts show little to no ruffling, but can form
circular dorsal ruffles in response to PDGF [92]. It has been shown that PAK1, a kinase activated by
Rac1 and Cdc42, plays a key role in PDGF-stimulated macropinocytosis in 3T3 fibroblasts [93]. The role
of WAVE proteins, which are regulators of actin polymerisation, in peripheral and dorsal ruffling has
been identified through studies of PDGF-stimulated mouse embryonic fibroblasts [94]. WAVE proteins
regulate ruffling through activation of the Arp2/3 complex, which nucleates actin polymerisation [94].
WAVE1 is required for dorsal ruffling whereas WAVE2 is required for peripheral ruffling [94].
3.4. Cells of the Nervous System
There have only been a handful of studies exploring macropinocytosis in cells of the nervous
system. However, these studies using primary neurons, neuron-like cell lines, primary microglia and
microglia cell lines, have all suggested a significant role for macropinocytosis in the physiology of
these cells as well as in the context of disease, and macropinocytosis represents an important emerging
topic in the neuroscience field.
3.4.1. Neurons
Macropinocytosis has been proposed to play a role in the spread of pathogenic protein aggregates
from neuron to neuron and the propagation of neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease and Huntington’s disease [95]. In C17.2 cells, a mouse neural precursor cell line,
tau fibrils, which represent one of the hallmarks of Alzheimer’s disease, can be internalised by a
macropinocytosis-like pathway, based on several lines of evidence including internalisation into large
vesicles (>5 µm in diameter) and a decrease in uptake following treatment with either EIP-amiloride or
cytochalasin D [96]. Interestingly, this pathway of tau fibril uptake is dependent on binding to cell
surface heparan sulfate proteoglycans (HSPGs); the existence of a HSPG-dependent macropinocytic
pathway is supported by studies of primary mouse hippocampal neurons, in which depletion of
Ext1, an enzyme involved in HSPG synthesis, reduces uptake of tau fibrils but not transferrin [96].
In contrast, another study showed that the uptake of tau aggregates by human induced pluripotent
stem cell (iPSC)-derived cerebral cortex neurons was not inhibited by cytochalasin D [97], indicating
that different pathways for internalisation of protein aggregates may be used in different neuronal
model systems. One of the pathogenic aggregates identified in amyotrophic lateral sclerosis (ALS),
namely superoxide dismutase 1 (SOD1), is internalised by macropinocytosis by both NSC-34 cells,
Membranes 2020, 10, 177 13 of 21
a mouse motor neuron-like cell line, and human iPSC-derived motor neurons [98]. In both cell models,
SOD1 aggregates stimulate ruffling and the uptake of 10 kDa dextran [98]. Macropinocytosis is also
potentially implicated in the aetiology of Alzheimer’s disease through the regulation of amyloid
precursor protein (APP) processing. SN56 cells, a hybrid cell line made from fusing dissociated
embryonic mouse septal neurons with N18TG2 neuroblastoma cells, internalise APP from the cell
surface into large vesicles (~1 µm in diameter) which traffic to lysosomes, raising the possibility that
macropinocytosis may be involved in the regulation of a pathway that leads to APP cleavage and
generation of toxic amyloid β peptides [99]. Dominant negative Arf6 reduces the internalisation of cell
surface APP and decreases amyloid β production, suggesting that Arf6 may regulate macropinocytosis
of APP [99].
Macropinocytosis also appears to regulate the dynamics of the growing or regenerating ends
of neuronal axons, called growth cones. Caffeine treatment has been used to study axon growth
inhibition and growth cone collapse, defined as a reduction in the surface area of a growth cone [100].
Caffeine-stimulation is associated with axon growth inhibition and growth cone collapse and the
formation of large vesicles which can be loaded with the fluid-phase marker, 10 kDa dextran, that are
trafficked back to the cell body [100]. These studies suggest that macropinocytosis promotes membrane
internalisation at growth cones and mediates growth cone collapse and axon growth inhibition [100].
Semaphorin 3A (collapsin-1) has been identified as a key mediator of macropinocytosis-induced axon
growth inhibition [100–102] by facilitating the degradation of syntaxin 1B, a negative regulator of
macropinocytosis [101]. Further support for a the role of macropinocytosis in growth cone collapse
comes from the finding that the dominant negative form of Rac1 inhibits semaphorin 3A-mediated
growth cone collapse and axon growth inhibition [102]. Macropinocytosis could also be relevant in
the context of neuron injury. Spinal cord injury causes neuron growth cones to become swollen and
distorted [103]. In vitro and in vivo analyses have shown that these axon endings are highly dynamic,
extending sheets of membrane resembling membrane ruffles, containing large (2–3 µm) intracellular
vesicles and internalising 10 kDa dextran, suggesting that these are sites of active macropinocytosis.
However, the precise role of macropinocytosis in the pathology of spinal injury and/or repair processes
remains unclear. Nonetheless, these studies suggest that macropinocytosis is important for the
maintenance of axons, and therefore potentially the formation of synaptic connections.
3.4.2. Microglia
Microglia are considered the “macrophages” of the brain and play key roles in immunity [104];
as such, they are good candidates for active macropinocytosis. This is supported by the observation that
resting rat microglia exhibit high levels of Lucifer yellow uptake both in vitro and in vivo, indicating
that these cells have high levels of pinocytosis, to which macropinocytosis may contribute [105].
The uptake of amyloid β by the macropinocytosis pathway in microglia is a key consideration for
the development of Alzheimer’s disease. BV-2 cells, an immortalised mouse microglia cell line, and
primary mouse microglia in vitro and in vivo can internalise soluble amyloid β [106]. For BV-2 cells,
the uptake of soluble amyloid β is considered to be mediated via a macropinocytosis-like mechanism,
as the uptake is nonsaturable and sensitive to cytochalasin D treatment [106]. Internalised soluble
amyloid β is trafficked to lysosomes for degradation [106]. Fluid-phase uptake of soluble amyloid β by
microglia is enhanced by various stimuli. For example, addition of nerve growth factor (NGF) to mouse
primary microglia increases macropinocytic uptake of 70 kDa dextran but not phagocytosis of 6 µm
beads, and increases uptake of soluble amyloid β but not fibrillar amyloid β [107]. Macropinocytosis
is also relevant to the uptake of exosomes by microglia. The mouse microglial cell line EOC-20 can
internalise exosomes in a process involving membrane ruffling and which is sensitive to amiloride
and cytochalasin D, suggesting that macropinocytosis is also a key pathway of exosome uptake in
microglia [108]. It is clear that macropinocytosis by microglia, as for macrophages, represents an
active pathway. However, an understanding of the physiological relevance of macropinocytosis by
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microglia in immune protection and in disease development in the central nervous system requires
further investigation.
3.5. Cancer Cells
Cancer cells are characterised by abnormal proliferation and by invasion into tissues in the body.
As a result of malignant invasion, tumours are often poorly vascularised and hypoxic, and therefore
require adaptive mechanisms to facilitate nutrient acquisition for sustained proliferation [109]. These
adaptive mechanisms include rewiring of metabolic pathways (e.g., increased utilisation of glycolysis,
i.e., the Warburg effect) and also the utilisation of macropinocytosis to facilitate nutrient uptake in
nutrient-poor environments. While certain aspects of macropinocytosis in cancer cells have already
been described in earlier sections, the role of macropinocytosis in nutrient acquisition by cancer cells
has been more extensively interrogated in other cancer cells. The role of macropinocytosis in cancer
cells and the therapeutic potential of targeting macropinocytosis in the treatment of cancer have been
recently reviewed in detail [110–112]. Here, we give a few examples as follows.
Compared to cells of normal tissue, human pancreatic ductal adenocarcinomas (PDACs) show
increased levels of macropinocytosis, as indicated by increased internalisation of high-molecular-weight
dextran [109]. Furthermore, the mouse pancreatic cancer cell line KRPC can derive amino acids from
the proteolytic degradation of extracellular albumin to sustain their proliferation [109]. The authors
showed that these adenocarcinoma cells were able to proliferate in the absence of essential amino acids
in the medium as a consequence of lysosomal degradation of extracellular albumin. The acquisition
of these amino acids from extracellular albumin is inhibited by EIP-amiloride, suggesting that
macropinocytosis is used by pancreatic cancer cells to scavenge extracellular proteins such as
albumin to fuel proliferation [109]. The in vivo relevance of macropinocytosis by cancer cells is
also demonstrated by analysis of the growth of tumour xenografts. Mouse xenografts of the human
pancreatic adenocarcinoma cell line (MIA PaCa-2) showed reduced high-molecular-weight dextran
uptake after treatment of mice with EIP-amiloride and, in addition, tumours were smaller compared to
controls [16], suggesting that inhibition of macropinocytosis in vivo may be a viable option for the
treatment of susceptible cancers. As macropinocytosis is nonspecific, this pathway can also facilitate
the uptake of other molecules which mediate cancer cell proliferation and survival, for instance, uptake
of ATP by A549 human lung epithelial cancer cells, as demonstrated by the co-localisation of fluorescent
ATP and the 70 kDa dextran marker of macropinocytosis [111]. Notably, inhibition of macropinocytosis
with EIP-amiloride increases the sensitivity of A549 cancer cells to the ATP competitive inhibitor
sunitinib [113].
The induction of constitutive macropinocytosis by oncogenic Ras appears to be a key feature
of numerous cancer cell types [16,109,113] (Figure 1D). In addition to sustaining the proliferation of
cancer cells through the acquisition of amino acids, macropinocytosis of extracellular nutrients can
also act as a sensor to drive the activation of the mTORC1 complex in mouse embryonic fibroblasts
(MEFs) expressing oncogenic K-Ras [114]. Following starvation of essential amino acids, extracellular
albumin promoted higher mTORC1 activity in MEF cells expressing oncogenic K-Ras compared
with wild-type K-Ras, a process inhibited by EIP-amiloride [112]. mTORC1 is a major signalling
complex that promotes cell proliferation [115]. Hence, constitutive macropinocytosis induced by
oncogenic Ras may be a mechanism of sustained mTORC1 activation and cell proliferation in cancer
cells [115]. Aside from oncogenic Ras, various other pathways can drive macropinocytosis in cancer
cells. A recent shRNA screen using three bladder cancer cell lines expressing wild-type Ras identified
the canonical Wnt signalling pathway, and transcription of β-catenin target genes, as a driver of
macropinocytosis [116]. In addition, oncogenic Src family kinases, involved in numerous cancers,
induce macropinocytosis [117,118]. Macropinocytosis is not only involved in cancer cell growth, but is
also implicated in cell death of aggressive gliobastoma cancer cells. Expression of constitutively active
H-Ras in U251 glioblastoma cells triggers the formation of abundant macropinosomes, resulting in
reduced viability and cell death [119]. This form of cell death associated with increased macropinocytosis
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is nonapoptotic and termed “methuosis” [119]. Constitutively active H-Ras also triggers enhanced
macropinocytosis and methuosis in several other human glioma cell lines, but not transformed HeLa,
HEp2 and HEK293 cells, demonstrating different requirements for the induction of macropinocytosis
in different cell types [119].
4. Conclusions
Macropinocytosis is critical to an ever-growing number of cellular processes, including but not
limited to antigen presentation, signalling, nutrient acquisition, nutrient sensing and pathogen invasion.
While macropinocytosis has been well studied in dendritic cells and macrophages, it is also becoming
increasingly apparent that macropinocytosis occurs in, and is physiologically relevant to, a much wider
range of cell types, including cells of the adaptive immune system, polarised endothelial and epithelial
cells, cells of the nervous system and cancer cells. Studies of these systems have revealed not only the
diversity of macropinocytosis-dependent functions, but also the existence of different macropinocytic
pathways that are initiated under different conditions and stimuli and that are regulated by different
molecular machinery. The identification of two distinct macropinocytosis pathways in macrophages,
derived from distinct types of membrane ruffling, namely dorsal and peripheral ruffling, highlights
the complexity of these pathways, which in turn reflect distinct functional attributes. Clearly, a deeper
understanding of the stimuli, regulators and the fate of the macropinocytic pathways in different cell
types is now required to fully appreciate the underlying cell biology and physiology.
In spite of recent advances, our understanding of the function and mechanism of macropinocytosis
in different cell types is still in its infancy. This is partly due to insufficient information on
macropinocytosis in primary cells, but also due to the absence of macropinosome-specific markers
and the absence of drugs that can specifically modulate macropinocytosis both in vitro and in vivo.
Identification of novel molecular machinery regulating macropinocytosis will aid future studies
and may pave the way to specifically modulate macropinocytosis in vitro and in vivo. With the
application of small-molecule inhibitors [55], siRNA libraries [120] and CRISPR libraries, there are
exciting opportunities for high-throughput screens to be performed to identify novel macropinocytosis
regulators. Ultimately, a greater understanding of the different pathways of macropinocytosis in
different cell types will provide the potential to modulate individual functions which are regulated by
these endocytic pathways.
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